Literature DB >> 20493569

The role of Human papillomavirus in head and neck cancer and the impact on radiotherapy outcome.

Pernille Lassen1.   

Abstract

The profound influence of Human papillomavirus (HPV) on the epidemiological pattern and clinical course of head and neck cancer (HNSCC) has led to a change in the traditional understanding of this disease entity. Separate therapeutic strategies based on tumour HPV status are under consideration and in this light provision of knowledge concerning the influence of tumour HPV on the radiation response in HNSCC appears highly relevant. This review provides a summary of the current understanding of the role of HPV in head and neck cancer with specific focus on the viral impact on radiotherapy outcome of HNSCC. Copyright 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20493569     DOI: 10.1016/j.radonc.2010.04.022

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  51 in total

Review 1.  Review of the clinical and biologic aspects of human papillomavirus-positive squamous cell carcinomas of the head and neck.

Authors:  Grace C Blitzer; Molly A Smith; Stephen L Harris; Randall J Kimple
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-03-15       Impact factor: 7.038

2.  Role of human papillomavirus in the pathogenesis of oral squamous cell carcinoma.

Authors:  Anastasios K Markopoulos
Journal:  World J Exp Med       Date:  2012-08-20

3.  Occult Primary Head and Neck Squamous Cell Carcinoma: Utility of Discovering Primary Lesions.

Authors:  Kara S Davis; J Kenneth Byrd; Vikas Mehta; Simon I Chiosea; Seungwon Kim; Robert L Ferris; Jonas T Johnson; Umamaheswar Duvvuri
Journal:  Otolaryngol Head Neck Surg       Date:  2014-05-08       Impact factor: 3.497

4.  Development and characterization of HPV-positive and HPV-negative head and neck squamous cell carcinoma tumorgrafts.

Authors:  Randall J Kimple; Paul M Harari; Alexandra D Torres; Robert Z Yang; Benjamin J Soriano; Menggang Yu; Eric A Armstrong; Grace C Blitzer; Molly A Smith; Laurel D Lorenz; Denis Lee; David T Yang; Timothy M McCulloch; Gregory K Hartig; Paul F Lambert
Journal:  Clin Cancer Res       Date:  2012-12-18       Impact factor: 12.531

5.  Cell growth inhibition in HPV 18 positive uveal melanoma cells by E6/E7 siRNA.

Authors:  Biyun Cun; Xin Song; Renbing Jia; Haibo Wang; Xiaoping Zhao; Bo Liu; Shengfang Ge; Xianqun Fan
Journal:  Tumour Biol       Date:  2013-03-14

6.  Intensity-modulated proton beam therapy (IMPT) versus intensity-modulated photon therapy (IMRT) for patients with oropharynx cancer - A case matched analysis.

Authors:  Pierre Blanchard; Adam S Garden; G Brandon Gunn; David I Rosenthal; William H Morrison; Mike Hernandez; Joseph Crutison; Jack J Lee; Rong Ye; C David Fuller; Abdallah S R Mohamed; Kate A Hutcheson; Emma B Holliday; Nikhil G Thaker; Erich M Sturgis; Merrill S Kies; X Ronald Zhu; Radhe Mohan; Steven J Frank
Journal:  Radiother Oncol       Date:  2016-06-21       Impact factor: 6.280

7.  Identification of methylation markers for the prediction of nodal metastasis in oral and oropharyngeal squamous cell carcinoma.

Authors:  L J Melchers; M J A M Clausen; M F Mastik; L Slagter-Menkema; J E van der Wal; G B A Wisman; J L N Roodenburg; E Schuuring
Journal:  Epigenetics       Date:  2015       Impact factor: 4.528

8.  Stereotactic body radiotherapy for recurrent oropharyngeal cancer - influence of HPV status and smoking history.

Authors:  Kara S Davis; John A Vargo; Robert L Ferris; Steven A Burton; James P Ohr; David A Clump; Dwight E Heron
Journal:  Oral Oncol       Date:  2014-08-28       Impact factor: 5.337

9.  Histones: Controlling Tumor Signaling Circuitry.

Authors:  Manoela D Martins; Rogerio M Castilho
Journal:  J Carcinog Mutagen       Date:  2013-07-29

Review 10.  Modulation of therapeutic sensitivity by human papillomavirus.

Authors:  Adam D Swick; Anirban Chatterjee; Anna-Maria A De Costa; Randall J Kimple
Journal:  Radiother Oncol       Date:  2015-09-10       Impact factor: 6.280

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.